Enantiomer

Enantiomer designates one of two mirror-image forms of a chiral molecule that cannot be superimposed, often exhibiting different biological activity, safety profiles, or pharmacokinetics despite identical chemical composition. Many small molecule drugs contain chiral centres, producing enantiomers that may differ in receptor binding, metabolism, or toxicity, making stereochemical control essential in pharmaceutical development.

The pharmaceutical industry addresses enantiomer considerations through chiral synthesis, resolution techniques, and analytical characterisation ensuring consistent stereochemical composition. Development programmes evaluate whether single-enantiomer products provide advantages over racemic mixtures through improved safety, reduced dose requirements, or enhanced efficacy. Regulatory submissions include stereochemical control strategies, impurity profiles, and analytical methods such as chiral HPLC or capillary electrophoresis demonstrating enantiomeric purity. Manufacturing must maintain consistent stereochemical outcomes at scale. As drug design increasingly targets highly specific binding interactions, stereochemistry remains fundamental to achieving optimal therapeutic performance.